You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
輝瑞尋求FDA批準新冠疫苗加強針
阿思達克 07-09 08:53
輝瑞(PFE.US)計劃要求美國食品及藥物管理局(FDA)在下月批準民衆接種新冠疫苗加強劑,因有更顯着的證據證明在接種疫苗6個月後感染的風險增加,同時高傳染性Delta型變種病毒正在傳播。

此前以色列政府發表報告,稱6月份發現輝瑞疫苗在預防感染的保護率降至64%。輝瑞首席科學官Mikael Dolsten表示,保護率下降主要是由於在1月或2月接種疫苗的人士受到感染,強調疫苗對Delta型變種病毒非常有效,但在6個月後抗體會減弱,接種人士可能存在感染的風險。

他稱,歐洲及其他國家已經與輝瑞接洽,討論加強劑的安排,有些國家可能會在美國授權注射加強針前就開始接種的安排,強調注射加強針對年齡較大的人士尤其重要。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account